Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

GlaxoSmithKline Add to portfolio

NYA:GSK, Jan 29, 05:53 UTC

Latest NYA:GSK News

Filter your feed

Apply Filter

Friday, January 24


News

CENTRAL TRUST Co Sells 2,925 Shares of GlaxoSmithKline plc (NYSE:GSK) – Riverton Roll

GSK GSK

CENTRAL TRUST Co lessened its position in GlaxoSmithKline plc (NYSE:GSK) by 19.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 12,233 shares of the pharmaceutical company’s stock after selling 2,925 shares during the period. Fisher Asset Management LLC now owns 15,267,588 shares of the pharmaceutical company’s stock valued at $651,621,000 after purchasing an additional 1,412,368 shares in the last quarter. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and six have assigned a buy rating to the stock.

Read Full Details

Topics:
  • Business
  • Financial
  • Health
News

GlaxoSmithKline (GSK) – Analysts’ Weekly Ratings Changes – Riverton Roll

GSK GSK

Several brokerages have updated their recommendations and price targets on shares of GlaxoSmithKline (LON: GSK) in the last few weeks:. 1/16/2020 – GlaxoSmithKline had its price target raised by analysts at Credit Suisse Group AG from GBX 1,800 ($23.68) to GBX 1,860 ($24.47). GlaxoSmithKline plc has a 1 year low of GBX 1,429.80 ($18.81) and a 1 year high of GBX 1,850.40 ($24.34). The business has a 50 day simple moving average of GBX 1,775.05 and a two-hundred day simple moving average of GBX 1,704.40.

Read Full Details

Topics:
  • Business
  • Financial

Thursday, January 16


News

GlaxoSmithKline plc 2.4% Potential Upside Indicated by Credit Suisse

GSK GSK +1 more GSK GSK ASHM

GlaxoSmithKline plc 2.4% Potential Upside Indicated by Credit Suisse. GlaxoSmithKline plc using EPIC/TICKER code (LON:GSK) had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘NEUTRAL’ today by analysts at Credit Suisse. This would imply the analyst believes there is now a potential upside of 2.4% from today’s opening price of 1815.8 GBX. GlaxoSmithKline plc has a 50 day moving average of 1,767.34 GBX and a 200 day moving average of 1,677.72.

Read Full Details

Topics:
  • Business
  • Financial

Monday, January 13


News

GlaxoSmithKline CEO seeks FDA approval for 'at least' six drugs in 2020

GSK GSK +1 more GSK GSK FB

Keep Me Logged In. GlaxoSmithKline CEO expects to get 'at least' six drug approvals from the FDA in 2020. GlaxoSmithKline CEO Emma Walmsley told "Mad Money" host Jim Cramer the British drugmaker has received "positive data" for cancer and HIV drugs. Top Videos. Technician: JPMorgan has looked 'too good' for much too long. Phase one trade deal expected to be signed on Jan. 15. S&P 500 and Nasdaq close at record highs. Watch CNBC's full interview with ImClone Systems founder Sam Waksal. What investors should know ahead of Big Banks earnings.

Read Full Details

Story Sources

cnbc.com cnbc.com
Topics:
  • Business
  • Health
  • Financial

Saturday, January 04


News

GlaxoSmithKline (LON:GSK) Given a GBX 2,110 Price Target at HSBC – Slater Sentinel

GSK GSK +4 more GSK GSK 0005 HSBA BVIC HSBC

GlaxoSmithKline (LON:GSK) has been assigned a GBX 2,110 ($27.76) target price by equities research analysts at HSBC in a report released on Wednesday, December 18th, Borsen Zeitung reports. HSBC’s target price indicates a potential upside of 18.25% from the stock’s current price. Credit Suisse Group raised their price target on shares of GlaxoSmithKline from GBX 1,700 ($22.36) to GBX 1,800 ($23.68) and gave the stock a “neutral” rating in a report on Thursday, October 31st. GlaxoSmithKline stock traded up GBX 7.20 ($0.09) during midday trading on Wednesday, reaching GBX 1,784.40 ($23.47).

Read Full Details

Topics:
  • Business
  • Financial

Thursday, January 02


News

2020 Antacids Global Market Report with Profiles of Leading Players GlaxoSmithKline, Pfizer and Bayer

BAYN GSK +2 more BAYN GSK PFE GSK

DUBLIN, Jan. 2, 2020 /PRNewswire/ -- The "Antacids Global Market Report 2020" report has been added to ResearchAndMarkets.com's offering. The global antacids market was valued at about $4.62 billion in 2018 and is expected to decline to $4.55 billion at a CAGR of -0.4% through 2022. Poor lifestyle choices involve deskbound jobs, poor quality of sleep and irregular dietary habits, which result in an increase in acidity level of the stomach and lead to gastroesophageal reflux disease. The side effects related to antacids is a major restraint for the antacids market. Some of the common side effects of antacids include dose-dependent rebound hyperacidity and milk-alkali syndrome.

Read Full Details

Topics:
  • Business
  • Health
  • Science
  • Financial

Tuesday, December 31


News

Bavarian Nordic Announces Closing of Acquisition of Rabipur/RabAvert and Encepur from GlaxoSmithKline and Updates Year-end Cash Preparedness Copenhagen Stock Exchange:BAVA

GSK GSK

COPENHAGEN, Denmark, December 31, 2019 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that it has completed the acquisition of the manufacturing and global rights1 to the two commercial vaccines, Rabipur®/RabAvert® and Encepur®, from GlaxoSmithKline plc (GSK), announced on October 21, 2019. The upfront payment is initially financed using the Company’s existing cash and bridge financing provided by Citi and Nordea. As previously announced, to support the acquisition, including repayment of the bridge financing, the Company has planned a rights issue of approximately EUR 350 million on Nasdaq Copenhagen in the first half of 2020. Consequently, the Company is adjusting its expectations to the 2019 year-end cash preparedness from approximately DKK 1,000 million to approximately DKK 700 million. “With the acquisition now completed, we can truly begin the commercial transformation of Bavarian Nordic, driven by established and proven commercial products, which along with our smallpox and monkeypox vaccine create a leading infectious disease franchise that will drive sustained profits and growth in the years ahead,” said Paul Chaplin, President and Chief Executive Officer of Bavarian Nordic.

Read Full Details

Topics:
  • Business
  • Financial

Monday, December 30


News

Drugs for Non-small Cell Lung Cancer Market- increasing demand with Industry Professionals Bristol-Myers Squibb , GlaxoSmithKline

GSK GSK +1 more GSK GSK BMY

The market study is sized with regional and country level break for historical and forecast period by revenue and volume and price analysis, stay tuned with the latest updates from the research insights – know more which territory is stealing market share gains in coming years. ***Sub Regions Included: North America [United States, Canada, Mexico], Asia-Pacific [China, India, Japan, South Korea, Australia, Indonesia, Malaysia, Philippines, Thailand, Vietnam], Europe [Germany, France, UK, Italy, Russia, Rest of Europe], South America [Brazil, Argentina, Rest of South America], Middle East & Africa [GCC Countries, Turkey, Egypt, South Africa, Rest of Middle East & Africa]. Both primary and secondary approach are used and detailed product portfolio / service offering were analysed and have been presented in a separate chapter of competitive landscape along with company profile. Some of the competitors identified in the Global Drugs for Non-small Cell Lung Cancer Market study include Bristol-Myers Squibb , GlaxoSmithKline , Menarini , Sanofi , Ziopharm Oncology , Alchemia , Amgen , Apotex , BioMarin Pharmaceutical , CellAct Pharma , Cerulean Pharma , Cipla , Cornerstone Pharmaceuticals , Curis , CytRx , Eli Lilly , Exelixis , Fresenius Kabi , Genentech , Hikma Pharmaceuticals , Hospira , Intas Pharmaceuticals , Karyopharm Therapeutics , Kyowa Hakko Kirin & Ligand Pharmaceuticals. Filed Under: General NewsTagged With: Drugs for Non-small Cell Lung Cancer Austria Market, Drugs for Non-small Cell Lung Cancer France Market, Drugs for Non-small Cell Lung Cancer Germany Market, Drugs for Non-small Cell Lung Cancer Market Analysis, Drugs for Non-small Cell Lung Cancer Market Research, Drugs for Non-small Cell Lung Cancer Spain Market, Drugs for Non-small Cell Lung Cancer UK Market.

Read Full Details

Topics:
  • Business
  • Financial

Saturday, December 28


News

British Land (LON:BLND) Price Target Increased to GBX 630 by Analysts at Deutsche Bank – Slater Sentinel

GSK GSK +1 more GSK GSK DBK

British Land (LON:BLND) had its target price boosted by equities research analysts at Deutsche Bank from GBX 580 ($7.63) to GBX 630 ($8.29) in a report released on Wednesday, December 18th, Stock Target Advisor reports. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and two have issued a buy rating to the company’s stock. British Land has a twelve month low of GBX 465.30 ($6.12) and a twelve month high of GBX 649.40 ($8.54). In other British Land news, insider William Jackson purchased 1,995 shares of British Land stock in a transaction that occurred on Monday, October 7th.

Read Full Details

Topics:
  • Business
  • Financial

Monday, December 23


News

The Zacks Analyst Blog Highlights: JPMorgan, Boeing, NVIDIA, AstraZeneca and GlaxoSmithKline

GSK AZN +5 more GSK AZN GSK BA NVDA JPM AZN

Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: JPMorgan Chase JPM, Boeing BA, NVIDIA NVDA, AstraZeneca AZN and GlaxoSmithKline GSK. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. The Zacks analyst believes that decent loan demand, acquisition of InstaMed, opening of new branches and focus on strengthening credit card business will aid financials.

Read Full Details

Topics:
  • Business
  • Financial